The FDA has approved GlaxoSmithKline’s blockbuster cancer drug Opdivo (nivolumab) in combination with chemotherapy for adult patients with resectable nonsmall-cell lung cancer (NSCLC). It is the first approved neoadjuvant treatment for patients with early-stage NSCLC.
Source: Drug Industry Daily